Molecular Targeting of Platelet-Derived Growth Factor B by Imatinib Mesylate in a Patient With Metastatic Dermatofibrosarcoma Protuberans
| Autor: | Sohail K. Mirza, Janet F. Eary, James D. Bruckner, Ernest U. Conrad, Scott M. Schuetze, Thomas H. Norwood, Brian P. Rubin |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male Cancer Research Skin Neoplasms medicine.drug_class Antineoplastic Agents Piperazines Tyrosine-kinase inhibitor medicine Dermatofibrosarcoma protuberans Humans Spinal Cord Neoplasms Radionuclide Imaging Fluorodeoxyglucose PDGFB business.industry Dermatofibrosarcoma Imatinib Proto-Oncogene Proteins c-sis Giant-cell fibroblastoma medicine.disease Pyrimidines Imatinib mesylate Oncology Benzamides Imatinib Mesylate Cancer research business Tyrosine kinase medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 20:3586-3591 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2002.01.027 |
| Popis: | PURPOSE: Dermatofibrosarcoma protuberans is caused by activation of the platelet-derived growth factor B (PDGFB) receptor, a transmembrane tyrosine kinase. We investigated the response of dermatofibrosarcoma protuberans to the tyrosine kinase inhibitor imatinib mesylate. PATIENTS AND METHODS: A patient with unresectable, metastatic dermatofibrosarcoma protuberans received imatinib mesylate (400 mg bid). Response to therapy was assessed by [18F]fluorodeoxyglucose (FDG) positron emission tomography, magnetic resonance imaging, and histopathologic and immunohistochemical evaluation. RESULTS: The patient was treated for 4 months with imatinib mesylate. The hypermetabolic uptake of FDG fell to background levels within 2 weeks of treatment, and the tumor volume shrank by over 75% during the 4 months of therapy, allowing for resection of the mass. There was no residual viable tumor in the resected specimen, indicating a complete histologic response to treatment with imatinib mesylate. CONCLUSION: Imatinib mesylate is highly active in dermatofibrosarcoma protuberans. The dramatic response seen in this patient demonstrates that inhibition of PDGFB receptor tyrosine kinase activity can significantly impact viability of at least one type of solid tumor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|